HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Guidance Could Impose Drug-Like Burden On Cosmetic Trials

This article was originally published in The Rose Sheet

Executive Summary

An FDA guidance document intended to clarify if firms conducting certain drug studies involving human subjects are obligated to file Investigational New Drug Applications instead raises questions for the cosmetics industry.

You may also be interested in...



FDA Should Strike Cosmetics From IND Guidance – Industry Counsel

By misstating elements of the U.S. Food, Drug and Cosmetic Act, FDA’s guidance on Investigational New Drug applications is in violation of the law, the Personal Care Products Council’s legal head says. FDA surprised stakeholders by including IND requirements for cosmetics in a final guidance released in late 2013, subsequently opening the section up for comments, which were due April 7.

In Brief: IND Applications For Cosmetic Trials? Lauder Appointment; P&G At Olympics

Comments may be submitted through April 7 regarding cosmetics-related sections in an FDA guidance that could impose the costs and burden of Investigational New Drug application on beauty companies conducting clinical trials. More news in brief.

FDA: “Extreme” Anti-Aging Claims Led To 2012 Warning Letters

A proliferation of “extreme” anti-aging cosmetic claims that crossed the line into drug territory led to FDA’s cluster of warning letters in 2012, according to Jennifer Thomas, director of the division of enforcement in the Center for Food Safety and Applied Nutrition’s office of compliance,

Related Content

UsernamePublicRestriction

Register

RS019226

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel